X

Given the current situation, we understand that people may experience worry and even fear about how their disease and treatment may impact their personal risk. Sanofi Genzyme is committed to patient safety and to transparent communication. We are taking COVID-19 seriously, and we are committed to updating the communities we serve with relevant information related to our medicines to help inform health decisions.

As COVID-19 has emerged only recently, there are no available data regarding the impact of the virus on our current therapies. At this time, if you have general questions about our therapies, you should consult the current U.S. Prescribing Information (USPI).

Each patient’s situation is unique, and patients and their healthcare providers are in the best position to make decisions regarding their care. In addition to local public health authority guidance, and local guidance from medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s (WHO) website.

MAT-US-2001111

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

Watch videos and read articles from real people living with relapsing MS

SPEAKING UP FOR YOURSELF

Expressing your relapsing MS treatment goals to your healthcare team is the key to finding out if a medication like LEMTRADA could be right for you.


Watch videos and read articles from real people who have received LEMTRADA to treat their relapsing multiple sclerosis

MAKING A CHOICE

Learn how people with relapsing MS chose to start treatment with LEMTRADA and what they considered when making their decisions.


Watch videos and read articles from real LEMTRADA patients

LEMTRADA EXPERIENCES

Learn about LEMTRADA treatment experiences directly from the people who have received it and the healthcare providers who prescribe it. Individual experiences may vary.


Watch videos and read articles from real people living with relapsing MS and their support partners

EMBRACING SUPPORT

Navigating the challenges of relapsing MS is difficult to do on your own. It's important to recognize the help that's available to you and your support partners.


Important Safety Information See More

LEMTRADA can cause serious side effects including serious autoimmune problems. Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include: